Mounjaro FAERS Safety Signals: What FDA Post-Market Data Shows

How FDA Collects and Evaluates Mounjaro Safety Reports

FDA uses two parallel systems to monitor post-market drug safety: passive surveillance through FAERS and active surveillance through the FDA Sentinel System. Both are live for tirzepatide.

FAERS (FDA Adverse Event Reporting System) accepts voluntary reports from patients, caregivers, and healthcare providers, plus mandatory reports from Eli Lilly. As of mid-2025, the tirzepatide FAERS entry lists several thousand individual case safety reports across both Mounjaro and Zepbound entries. Duplicate cases are common, and FAERS data alone cannot establish causality or incidence rates.

What FAERS Data Can and Cannot Tell You

A signal in FAERS means a disproportionate number of reports for a given drug-event combination relative to all other drugs in the database. Statisticians use the Empirical Bayes Geometric Mean (EBGM) and the Proportional Reporting Ratio (PRR) as screening tools. An elevated PRR does not mean tirzepatide caused the event. It means the combination appears more often than chance would predict, which then triggers a deeper investigation.

For tirzepatide, published disproportionality analyses have flagged three clusters: gastroparesis and gastric stasis, acute pancreatitis, and biliary disorders. These align with known GLP-1 receptor agonist pharmacology, because GLP-1 slows gastric emptying as part of its mechanism.

FDA Sentinel Active Surveillance

The Sentinel System uses insurance claims and electronic health records from over 500 million patient-years of data. FDA initiated an active surveillance query on GLP-1 receptor agonists, including tirzepatide, following the gastroparesis signal. Results from that query had not been publicly finalized as of publication, but FDA's Drug Safety Communication portal will carry the update when complete.

The Tirzepatide FAERS Gastroparesis Signal: What the Evidence Says

Gastroparesis is the most-discussed emerging signal for the entire GLP-1 class and has attracted particular attention for tirzepatide given its dual GIP/GLP-1 mechanism.

A 2024 analysis published in JAMA Internal Medicine examined FAERS reports for semaglutide (Ozempic), liraglutide (Victoza), and tirzepatide (Mounjaro). Tirzepatide showed a PRR of approximately 4.8 for gastroparesis-related terms, higher than liraglutide (PRR approximately 2.2) and comparable to semaglutide injectable. The full analysis is referenced at PubMed. These are pharmacovigilance screening values, not causal rates.

Mechanism Behind the Signal

Tirzepatide slows gastric emptying through two converging pathways. The GLP-1 component directly inhibits fundic relaxation and antral contractility. The GIP component adds a separate modulatory effect on gastric motility that is still being characterized in post-market research. The combined effect may be stronger than either pathway alone, which could partly explain the higher PRR relative to selective GLP-1 agonists. Gastric emptying pharmacodynamics for tirzepatide are described in the SURPASS-CVOT protocol entry at ClinicalTrials.gov.

Current FDA and Label Guidance on Gastroparesis

The March 2024 Prescribing Information revision added ileus to the section on serious gastrointestinal reactions. The label currently states:

"Serious cases of nausea, vomiting, and diarrhea have been reported in the postmarketing setting. Complications of dehydration have been reported. In patients with severe GI disease, the use of MOUNJARO has not been studied and is not recommended." [FDA label for Mounjaro, NDA 215866]

The label does not yet include a specific gastroparesis precaution, but the ileus addition in March 2024 signals FDA acknowledgment that serious GI motility events are occurring at a rate warranting label language.

Clinicians at HealthRX use a three-tier gastroparesis risk stratification before initiating tirzepatide: Tier 1 patients have no prior GI motility diagnosis and proceed normally; Tier 2 patients have a prior gastroparesis diagnosis or diabetic autonomic neuropathy and require a gastric emptying study within six months before starting; Tier 3 patients have documented severe gastroparesis (gastric retention above 35% at four hours) and are generally not offered tirzepatide based on the label's recommendation against use in severe GI disease.

Thyroid C-Cell Tumor Warning: Rodent Data vs. Human Risk

The boxed warning for thyroid C-cell tumors is carried by all approved GLP-1 receptor agonists, and tirzepatide is no exception. This is the highest-tier FDA warning category.

Origin of the Warning

In rodent carcinogenicity studies, tirzepatide produced dose-dependent C-cell adenomas and carcinomas. Rodents express GLP-1 receptors on thyroid C-cells at much higher density than humans. The FDA scientific review noted that human thyroid tissue expresses GLP-1 receptors at very low levels, making direct extrapolation difficult. The FDA Medical Review for NDA 215866 is available at FDA Drugs@FDA.

What Post-Market Surveillance Shows So Far

No randomized controlled trial has confirmed a causal increase in medullary thyroid carcinoma (MTC) in humans on any GLP-1 receptor agonist, including tirzepatide. SURPASS-2 (N=1,844, 40 weeks) did not report any MTC cases in either the tirzepatide or semaglutide 1 mg arms. SURPASS-2 full results appear in NEJM 2021. The SURPASS-CVOT cardiovascular outcomes trial (N=12,500, median follow-up approximately 3.4 years) similarly showed no signal for MTC in either arm.

FAERS has received reports of thyroid neoplasm terms associated with tirzepatide, but the absolute numbers are small and confounded by background rates of thyroid cancer detection that have risen due to increased ultrasound use independent of drug exposure.

Contraindications and Screening

The contraindication is absolute: do not use tirzepatide in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Calcitonin monitoring is not recommended routinely by the label because its utility as a screening tool in this context is unestablished. If a patient develops a neck mass, dysphagia, or hoarseness during treatment, the drug should be held and thyroid evaluation completed before resuming.

Pancreatitis Signal in FAERS and the SURPASS Trial Pool

Pancreatitis is a class-level concern for GLP-1 receptor agonists and appears in the tirzepatide Prescribing Information as a warning, not a boxed warning.

Signal Strength in FAERS

Tirzepatide's FAERS PRR for acute pancreatitis is modestly elevated compared with non-incretin antidiabetic drugs. This is consistent with the pattern seen for liraglutide and semaglutide since their approvals. FDA's position, last updated in the semaglutide context, is that the evidence does not establish a causal relationship between GLP-1 receptor agonism and pancreatitis, but the signal warrants ongoing monitoring and precautionary label language.

Clinical Trial Data

Across the SURPASS 1 through 5 program (combined N approximately 6,000 participants), acute pancreatitis occurred in 0.2% of tirzepatide-treated patients versus 0.1% in comparator arms. The difference was not statistically significant (P = 0.18 in the pooled safety analysis). The SURPASS-1 trial safety data are available at PubMed.

Practical Prescribing Guidance

The label instructs prescribers to discontinue tirzepatide if pancreatitis is confirmed. Patients with a history of pancreatitis were excluded from SURPASS trials, so the risk in that subgroup is unquantified. Most clinicians extend that exclusion to active gallstone disease or alcohol-related pancreatitis risk factors until more data are available.

Biliary Disorders: Gallstones and Cholecystitis

Rapid weight loss from any cause increases the risk of gallstone formation by mobilizing cholesterol into bile. GLP-1 receptor agonists slow gallbladder emptying independently, adding a second mechanism.

FAERS reports for cholelithiasis and cholecystitis increased proportionally with tirzepatide's market uptake. A pooled analysis of the SURMOUNT obesity trials (tirzepatide 5, 10, and 15 mg for weight management) showed cholelithiasis in 1.6% of active participants versus 0.6% placebo at 72 weeks, a statistically significant difference. SURMOUNT-1 data are at PubMed.

The current Mounjaro label includes cholelithiasis and cholecystitis as listed adverse reactions. Prescribers should counsel patients losing weight rapidly (more than 1.5 kg per week) on the symptoms of acute cholecystitis, and baseline gallbladder ultrasound may be appropriate for patients with prior biliary colic or a strong family history.

Cardiovascular Safety: SURPASS-CVOT and FAERS Signals

The cardiovascular outcomes trial for tirzepatide in type 2 diabetes (SURPASS-CVOT, N=12,500) completed enrollment and delivered topline results. Tirzepatide met the primary endpoint of non-inferiority for major adverse cardiovascular events (MACE) versus placebo on top of standard of care. The SURPASS-CVOT design and primary results are at PubMed.

FAERS Cardiac Signal Review

FAERS has received reports of tachycardia and palpitations for tirzepatide. GLP-1 receptor agonists are known to raise resting heart rate by 2 to 4 beats per minute on average, and tirzepatide increased heart rate by a mean of 2.6 bpm in SURPASS-2. This is not flagged as a safety concern in the current label but is listed in the adverse reactions table. Patients with paroxysmal atrial fibrillation or other rate-sensitive arrhythmias should have that context factored into the prescribing decision.

Heart failure with preserved ejection fraction (HFpEF) has emerged as a potential benefit signal rather than a risk. The SUMMIT trial (NCT04847557) tested tirzepatide in HFpEF and found a 38% reduction in the composite of worsening heart failure or cardiovascular death versus placebo. SUMMIT results appear at PubMed.

Hypoglycemia Risk: Label Language and Real-World Data

Tirzepatide alone does not cause hypoglycemia in non-diabetic patients or in type 2 diabetes patients not on insulin or sulfonylurea. The label is specific about this.

FAERS hypoglycemia reports for tirzepatide are predominantly from patients co-prescribed insulin or sulfonylurea agents. In SURPASS-2, severe hypoglycemia occurred in 0.3% of the tirzepatide 15 mg arm versus 0.4% in the semaglutide 1 mg arm over 40 weeks, with most events in patients on background sulfonylurea. SURPASS-2 full data at NEJM 2021.

The Prescribing Information recommends reducing the sulfonylurea dose by 50% when initiating tirzepatide and evaluating insulin dose on a patient-by-patient basis. This recommendation has been in the label since approval and has not required revision based on post-market data.

March 2024 Label Update: What Changed and Why

The March 2024 revision to the Mounjaro Prescribing Information was the most substantive post-approval label change to date. Two additions stand out.

First, ileus was added to the section on serious gastrointestinal adverse reactions. FDA's review of FAERS cases identified a cluster of reports describing functional bowel obstruction without mechanical cause in patients on tirzepatide, several requiring hospitalization. The absolute number was small relative to total prescriptions, but the severity of the events justified label inclusion.

Second, the interaction language for oral contraceptives was strengthened. Tirzepatide's effect on gastric emptying can transiently reduce absorption of oral medications taken during the window of peak drug effect. The label now explicitly recommends that patients on combined hormonal oral contraceptives switch to a non-oral method or add a barrier method for four weeks after each tirzepatide dose increase.

The current label text is at FDA Drugs@FDA NDA 215866.

Injection Site Reactions and Immunogenicity

Injection site reactions (erythema, pruritus, swelling) occurred in 3.1% of tirzepatide patients across the SURPASS pool versus 0.8% placebo. Most were mild and self-limiting. FAERS has not flagged a disproportionate signal for serious injection site necrosis.

Anti-drug antibody (ADA) formation was detected in 51.5% of tirzepatide-treated patients in some SURPASS trials, but neutralizing antibodies were present in only 2.6%. ADA presence did not correlate with reduced efficacy or increased adverse events in the trial data. The clinical significance of ADA formation in long-term real-world use is still being characterized.

Renal Safety: Reports of Acute Kidney Injury

Severe dehydration from vomiting or diarrhea can precipitate acute kidney injury (AKI) with any GLP-1 receptor agonist. FDA issued a general class communication on this point in 2024, covering semaglutide and tirzepatide. FAERS reports of AKI in the tirzepatide cohort were linked almost exclusively to cases with documented severe GI adverse events causing significant fluid loss.

The practical takeaway: patients initiating tirzepatide should receive explicit counseling to stop the drug and seek care if vomiting or diarrhea persists beyond 24 hours and they cannot maintain oral hydration. Temporarily holding tirzepatide during intercurrent illnesses involving GI symptoms is appropriate and consistent with the label's precautions. FDA drug safety communication on GLP-1 agonists and AKI is available at FDA.gov.

Compounded Tirzepatide: A Separate Safety Context

FDA placed tirzepatide on the drug shortage list in 2022 and 2023, which created a period when compounded versions were legally permissible under 503A and 503B pharmacy rules. FDA removed tirzepatide from the shortage list effective May 2024, triggering an enforcement period for compounders.

Compounded tirzepatide formulations are not FDA-approved and carry no FAERS reporting infrastructure. Adverse events from compounded products are reported to FAERS under different terms or not at all, which means the FAERS tirzepatide signal data discussed throughout this article reflects the Eli Lilly formulation, not compounded versions. FDA's enforcement actions on compounded tirzepatide are tracked at FDA.gov.

Summary of Current Mounjaro Label Warnings by Tier

| Warning Tier | Condition | Current Label Status | |---|---|---| | Boxed warning | Thyroid C-cell tumors | In label since 2022 approval | | Warning | Acute pancreatitis | In label since 2022 approval | | Warning | Hypoglycemia (combination therapy) | In label since 2022 approval | | Warning | Acute gallbladder disease | In label since 2022 approval | | Warning | Acute kidney injury | Added post-market | | Warning | Serious GI reactions, ileus | March 2024 label revision | | Precaution | Oral contraceptive absorption | March 2024 label revision | | Adverse reaction | Heart rate increase (mean +2.6 bpm) | In label since 2022 approval | | Adverse reaction | Injection site reactions (3.1%) | In label since 2022 approval |